Rapport accelerates Phase 3 start for RAP-219 in focal seizures to Q2 2026; expands epilepsy portfolio into PGTCS

Rapport Therapeutics, Inc.

Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.
New epilepsy program in primary generalized tonic-clonic seizures (PGTCS); Phase 3 trial planned H1 2027.
FDA removed clinical hold on DPNP IND; Rapport defers further DPNP investment to prioritize α6β4 program.
$513M cash, cash equivalents and short-term investments as of Q3 2025; expected to fund operations into H2 2029.
Phase 2 bipolar mania trial on track for H1 2027 topline; long-acting injectable IND-enabling activities start Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.